We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Marker Found for Prostate and Colon Cancer

By Biotechdaily staff writers
Posted on 07 Aug 2002
Researchers have found large amounts of a protein in prostate, colon, and other tumor cells but not in normal cells, making the protein a cancer marker and a potential new diagnostic tool for doctors. More...
The findings were reported in the August 1, 2002, issue of the Journal of Clinical Investigation.

The protein interacts with the gene for Huntington's disease and is called huntingtin interacting protein, or HIP1.It has never before been associated with any type of cancer. The protein appears to be involved in the clathrin-mediated trafficking pathway, along with another protein called htt, which is expressed by the mutated gene responsible for Huntington's disease. The connection to the Huntingon's gene could be important, say the researchers, because people with Huntington's disease rarely get cancer.

"Originally, I thought HIP1 was a tumor-suppressor gene, but it could be a survival factor that prevents cancerous cells from dying or an oncogene causing normal cells to become cancerous,” notes Theodora S. Ross, M.D., Ph.D., an oncologist in the Comprehensive Cancer Center at the University of Michigan (Ann Arbor, USA) who has focused on HIP1 over the past three years. When the researchers made a mutant version of HIP1 by knocking off one segment, the result was massive cell death, suggesting that HIP1 is necessary for cell survival.

No significant HIP1 expression was found in normal prostate epithelial cells. However, as prostate cancer develops and progresses, there is a steady increase in HIP1 expression. "HIP1 was expressed in 50% of tumors from patients in the earliest stages of cancer, 88% of tumors from patients with localized breast cancer, and 100% of patients with metastatic prostate cancer,” says Dr. Ross. The expression pattern varied in melanoma, breast, and ovarian cancers but was consistently overexpressed.




Related Links:
Univ. of Michigan

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.